Donate

In the 1990’s USA: PSA Screening Reduced Instances of Initial Diagnosis of Metastatic Prostate Cancer By 50%

Screening for early cancer detection may reduce the rate of related metastatic disease, but not always. In a published study in the New England Journal of Medicine, researchers evaluated the incidence of men having a diagnosis of advanced, metastatic prostate cancer at the initial prostate cancer diagnosis. The researchers data from the Surveillance, Epidemiology, and [...]

Reporting A Concerning Increase In The Number Of Men Diagnosed With Advanced Prostate Cancer

According to information from a published report from the Tuesday, July 19, 2016 edition of HealthDay News, there has been an explosion of new cases of advanced prostate cancer in the United States. They reported on a study using data on nearly 800,000 men listed in the National Cancer Data Base who had been diagnosed [...]

Of Interest In the News – Surprise Out-of Network Bills and the U.S. Preventive Task Force Becomes Controversial

In an article in Time (3/7 Sweetland Edwards) there is a discussion about the failure of the Affordable Care Act to stop patients from receiving “surprise” bills from their medical providers for services provided. These surprises result from people going to a medical facility, which is in their Network but having some service, provided by [...]

SEER PSA Data Is Flawed and Removed By the NCI – What Are the Implications for the Flawed USPTF PSA Debacle?

I am not sure what to do with this information, but it certainly could be described as a rather large elephant in the room. We all are very familiar with the prostate cancer PSA test controversy brought on by the United States Preventive Task Force (USPTF). To quickly review the issue, the USPTF developed a [...]

The Current Status of the Debate on Prostate Cancer Screening

All of us in the prostate cancer world know that the U.S. Preventive Services Task Force (USPTF) has announced its recommendation against routine PSA screening for men. There remains much debate and unhappiness in both the medical community (urologists and oncologists) as well as in the prostate cancer community itself. There remains a lot of [...]

Go to Top